Tissue-type plasminogen activator modulates inflammatory responses and renal function in ischemia reperfusion injury

Journal of the American Society of Nephrology

Volumn 17, Issue 1, 2006, Pages 131-140

  Roelofs, Joris J T H ^a,c   Rouschop, Kasper M A ^a   Leemans, Jaklien C ^a   Claessen, Nike ^a   De Boer, Anita M ^a   Frederiks, Wilma M ^a   Lijnen, H Roger ^b   Weening, Jan J ^a   Florquin, Sandrine ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CELL ADHESION MOLECULE; CELL ADHESION MOLECULE 1; CHEMOKINE; COMPLEMENT COMPONENT C3; CYTOKINE; MATRIX METALLOPROTEINASE; PLASMIN; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG;

ACUTE KIDNEY FAILURE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME ACTIVITY; FIBRINOLYSIS; HISTOPATHOLOGY; INFLAMMATION; KIDNEY ARTERY; KIDNEY FUNCTION; KIDNEY INJURY; KIDNEY INTERSTITIUM; KIDNEY ISCHEMIA; KIDNEY PROXIMAL TUBULE; MOUSE; MOUSE STRAIN; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; REPERFUSION INJURY; STATISTICAL SIGNIFICANCE; UPREGULATION; WILD TYPE;

EID: 33645458568     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1681/ASN.2005010089     Document Type: Article

References (50)

1. Alkhunaizi AM, Schrier RW: Management of acute renal failure: New perspectives. Am J Kidney Dis 28: 315-328, 1996
2. Daemen MA, de Vries B, van't Veer C, Wolfs TG, Buurman WA: Apoptosis and chemokine induction after renal ischemia-reperfusion. Transplantation 71: 1007-1011, 2001
3. Bonventre JV, Zuk A: Ischemic acute renal failure: An inflammatory disease? Kidney Int 66: 480-485, 2004
4. Johnson KJ, Weinberg JM: Postischemic renal injury due to oxygen radicals. Curr Opin Nephrol Hypertens 2: 625-635, 1993
5. Collen D: The plasminogen (fibrinolytic) system. Thromb Haemost 82: 259-270, 1999
6. Stringer KA, Bose SK, McCord JM: Antiinflammatory activity of tissue plasminogen activator in the carrageenan rat footpad model. Free Radic Biol Med 22: 985-988, 1997
7. Montrucchio G, Lupia E, De Martino A, Silvestro L, Savu SR, Cacace G, De Filippi PG, Emanuelli G, Camussi G: Plasmin promotes an endothelium-dependent adhesion of neutrophils. Involvement of platelet activating factor and P-selectin. Circulation 93: 2152-2160, 1996
8. Baramova EN, Bajou K, Remade A, L'Hoir C, Krell HW, Weidle UH, Noel A, Foidart JM: Involvement of PA/plasmin system in the processing of pro-MMP-9 and in the second step of pro-MMP-2 activation. FEBS Lett 405: 157-162, 1997
9. Sappino AP, Huarte J, Vassalli JD, Belin D: Sites of synthesis of urokinase and tissue-type plasminogen activators in the murine kidney. J Clin Invest 87: 962-970, 1991
10. Kitching AR, Holdsworth SR, Ploplis VA, Plow EF, Collen D, Carmeliet P, Tipping PG: Plasminogen and plasminogen activators protect against renal injury in crescentic glomerulonephritis. J Exp Med 185: 963-968, 1997
11. Haraguchi M, Border WA, Huang Y, Noble NA: t-PA promotes glomerular plasmin generation and matrix degradation in experimental glomerulonephritis. Kidney Int 59: 2146-2155, 2001
12. Yang J, Shultz RW, Mars WM, Wegner RE, Li Y, Dai C, Nejak K, Liu Y: Disruption of tissue-type plasminogen activator gene in mice reduces renal interstitial fibrosis in obstructive nephropathy. J Clin Invest 110: 1525-1538, 2002
13. Carmeliet P, Schoonjans L, Kieckens L, Ream B, Degen J, Bronson R, De Vos R, van den Oord JJ, Collen D, Mulligan RC: Physiological consequences of loss of plasminogen activator gene function in mice. Nature 368: 419-424, 1994
14. Lijnen HR, Van Hoef B, Lupu F, Moons L, Carmeliet P, Collen D: Function of the plasminogen/plasmin and matrix metalloproteinase systems after vascular injury in mice with targeted inactivation of fibrinolytic system genes. Arterioscler Thromb Vasc Biol 18: 1035-1045, 1998
15. Roelofs JJ, Rowshani AT, Van Den Berg JG, Claessen N, Aten J, Ten Berge IJ, Weening JJ, Florquin S: Expression of urokinase plasminogen activator and its receptor during acute renal allograft rejection. Kidney Int 64: 1845-1853, 2003
16. Kim YH, Earm JH, Ma T, Verkman AS, Knepper MA, Madsen KM, Kim J: Aquaporin-4 expression in adult and developing mouse and rat kidney. J Am Soc Nephrol 12: 1795-1804, 2001
17. Rouschop KM, Roelofs JJ, Claessen N, da Costa Martins P, Zwaginga JJ, Pals ST, Weening JJ, Florquin S: Protection against renal ischemia reperfusion injury by CD44 disruption. J Am Soc Nephrol 16: 2034-2043, 2005
18. Arza B, Hoylaerts MF, Felez J, Collen D, Lijnen HR: Prostromelysin-1 (proMMP-3) stimulates plasminogen activation by tissue-type plasminogen activator. Eur J Biochem 267: 6378-6384, 2000
19. Mook OR, Van Overbeek C, Ackema EG, Van Maldegem F, Frederiks WM: In situ localization of gelatinolytic activity in the extracellular matrix of metastases of colon cancer in rat liver using quenched fluorogenic DQ-gelatin. J Histochem Cytochem 51: 821-829, 2003
20. Rouschop KM, Sewnath ME, Claessen N, Roelofs JJ, Hoedemaeker I, van der Neut R, Aten J, Pals ST, Weening JJ, Florquin S: CD44 deficiency increases tubular damage but reduces renal fibrosis in obstructive nephropathy. J Am Soc Nephrol 15: 674-686, 2004
21. Zhang RL, Zhang ZG, Chopp M, Zivin JA: Thrombolysis with tissue plasminogen activator alters adhesion molecule expression in the ischemic rat brain. Stroke 30: 624-629, 1999
22. Schaiff WT, Eisenberg PR: Direct induction of complement activation by pharmacologic activation of plasminogen. Coron Artery Dis 8: 9-18, 1997
23. Ito T, Takenaka K, Sakai H, Yoshimura S, Hayashi K, Noda S, Sakai N: Elevation of mRNA levels of tissue-type plasminogen activator and urokinase-type plasminogen activator in hippocampus and cerebral cortex following middle cerebral artery occlusion in rats. Neurol Res 22: 413-419, 2000
24. Wang YF, Tsirka SE, Strickland S, Stieg PE, Soriano SG, Lipton SA: Tissue plasminogen activator (tPA) increases neuronal damage after focal cerebral ischemia in wild-type and tPA-deficient mice. Nat Med 4: 228-231, 1998
25. Fujita T, Toda K, Karimova A, Yan SF, Naka Y, Yet SF, Pinsky DJ: Paradoxical rescue from ischemic lung injury by inhaled carbon monoxide driven by derepression of fibrinolysis. Nat Med 7: 598-604, 2001
26. Daemen MA, de Vries B, Buurman WA: Apoptosis and inflammation in renal reperfusion injury. Transplantation 73: 1693-1700, 2002
27. Stringer KA, Lindenfeld J, Repine AJ, Cohen Z, Repine JE: Tissue plasminogen activator (tPA) inhibits human neutrophil superoxide anion production in vitro. Inflammation 21: 27-34, 1997
28. Mehta JL, Mehta P, Lawson DL, Herzbrun L: Tissue plasminogen activator and plasmin independently decrease human neutrophil activation. Life Sci 45:1665-1669, 1989
29. Yamamoto K, Loskutoff DJ: The kidneys of mice with autoimmune disease acquire a hypofibrinolytic/procoagulant state that correlates with the development of glomerulonephritis and tissue microthrombosis. Am J Pathol 151: 725-734, 1997
30. Enestrom S, Druid H, Rammer L: Fibrin deposition in the kidney in post-ischaemic renal damage. Br J Exp Pathol 69: 387-394, 1988
31. Tabrizi P, Wang L, Seeds N, McComb JG, Yamada S, Griffin JH, Carmeliet P, Weiss MH, Zlokovic BV: Tissue plasminogen activator (tPA) deficiency exacerbates cerebrovascular fibrin deposition and brain injury in a murine stroke model: Studies in tPA-deficient mice and wild-type mice on a matched genetic background. Arteriosder Thromb Vasc Biol 19: 2801-2806, 1999
32. Zhou W, Farrar CA, Abe K, Pratt JR, Marsh JE, Wang Y, Stahl GL, Sacks SH: Predominant role for C5b-9 in renal ischemia/reperfusion injury. J Clin Invest 105: 1363-1371, 2000
33. Agostoni A, Gardinali M, Frangi D, Cafaro C, Conciato L, Sponzilli C, Salvioni A, Cugno M, Cicardi M: Activation of complement and kinin systems after thrombolytic therapy in patients with acute myocardial infarction. A comparison between streptokinase and recombinant tissue-type plasminogen activator. Circulation 90: 2666-2670, 1994
34. Oda T, Jung YO, Kim HS, Cai X, Lopez-Guisa JM, Ikeda Y, Eddy AA: PAI-1 deficiency attenuates the fibrogenic response to ureteral obstruction. Kidney M 60: 587-596, 2001
35. Cook AD, Braine EL, Campbell IK, Hamilton JA: Differing roles for urokinase and tissue-type plasminogen activator in collagen-induced arthritis. Am J Pathol 160: 917-926, 2002
36. Yang YH, Carmeliet P, Hamilton JA: Tissue-type plasminogen activator deficiency exacerbates arthritis. J Immunol 167: 1047-1052, 2001
37. Sanchez-Pernaute O, Largo R, Calvo E, Alvarez-Soria MA, Egido J, Herrero-Beaumont G: A fibrin based model for rheumatoid synovitis. Ann Rheum Dis 62: 1135-1138, 2003
38. Molitoris BA, Marrs J: The role of cell adhesion molecules in ischemic acute renal failure. Am J Med 106: 583-592, 1999
39. Singbartl K, Ley K: Protection from ischemia-reperfusion induced severe acute renal failure by blocking E-selectin. Crit Care Med 28: 2507-2514, 2000
40. Singbartl K, Green SA, Ley K: Blocking P-selectin protects from ischemia/reperfusion-induced acute renal failure. FASEB J 14: 48-54, 2000
41. Kelly KJ, Williams WW Jr, Colvin RB, Bonventre JV: Antibody to intercellular adhesion molecule 1 protects the kidney against ischemic injury. Proc Natl Acad Sci U S A 91: 812-816, 1994
42. Kelly KJ, Williams WW Jr, Colvin RB, Meehan SM, Springer TA, Gutierrez-Ramos JC, Bonventre JV: Intercellular adhesion molecule-1-deficient mice are protected against ischemic renal injury. J Clin Invest 97: 1056-1063, 1996
43. Everts M, Asgeirsdottir SA, Kok RJ, Twisk J, de Vries B, Lubberts E, Bos EJ, Wemer N, Mejer DK, Molema G: Comparison of E-selectin expression at mRNA and protein levels in murine models of inflammation. Inflamm Res 52: 512-518, 2003
44. De Greef KE, Ysebaert DK, Persy V, Vercauteren SR, De Broe ME: ICAM-1 expression and leukocyte accumulation in inner stripe of outer medulla in early phase of ischemic compared to HgC12-induced ARF. Kidney M 63: 1697-1707, 2003
45. Krapohl BD, Siemionow M, Zins JE: Effect of tissue-plasminogen activator on leukocyte-endothelial interactions at the microcirculatory level. Plast Reconstr Surg 102: 2388-2394, 1998
46. Pfefferkorn T, Rosenberg GA: Closure of the blood-brain barrier by matrix metalloproteinase inhibition reduces rtPA-mediated mortality in cerebral ischemia with delayed reperfusion. Stroke 34: 2025-2030, 2003
47. Wang X, Lee SR, Arai K, Tsuji K, Rebeck GW, Lo EH: Lipoprotein receptor-mediated induction of matrix metalloproteinase by tissue plasminogen activator. Nat Med 9: 1313-1317, 2003
48. Yepes M, Sandkvist M, Moore EG, Bugge TH, Strickland DK, Lawrence DA: Tissue-type plasminogen activator induces opening of the blood-brain barrier via the LDL receptor-related protein. J Clin Invest 112: 1533-1540, 2003
49. Zhang G, Kim H, Cai X, Lopez-Guisa JM, Alpers CE, Liu Y, Carmeliet P, Eddy AA: Urokinase receptor deficiency accelerates renal fibrosis in obstructive nephropathy. J Am Soc Nephrol 14: 1254-1271, 2003
50. Lenz O, Elliot SJ, Stetler-Stevenson WG: Matrix metallo-proteinases in renal development and disease. J Am Soc Nephrol 11: 574-581, 2000